Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBO-309 in acute ischemic stroke with tandem occlusion
NCT06813651Phase 2Recruiting
- Sponsor
- ThromBio
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD-6482 in ischemic stroke (3 arms), sponsored by ThromBio. Primary endpoint: Composite outcome of efficacy and safety at 36 hours. Started Oct 2025; status: recruiting.
02
Drugs
AZD-6482
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06813651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813651.